{"nctId":"NCT02172950","briefTitle":"An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A","startDateStruct":{"date":"2014-10-13"},"conditions":["Hemophilia A","Severe Hemophilia A"],"count":246,"armGroups":[{"label":"Previously treated patients (PTPs)","type":"EXPERIMENTAL","interventionNames":["Biological: rVIII-SingleChain"]},{"label":"Previously untreated patients (PUPs)","type":"EXPERIMENTAL","interventionNames":["Biological: rVIII-SingleChain"]}],"interventions":[{"name":"rVIII-SingleChain","otherNames":["CSL627"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPTPs:\n\n* Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \\< 1%) and who participated in a previous CSL-sponsored clinical study with rVIII-SingleChain.\n* Males 0 to \\<65 years age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \\< 1%), who have at least 50 EDs to any FVIII product, and who are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain.\n\nPUPs:\n\n* Males 0 to \\<18 years of who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \\< 1%)\n* No prior exposure to any Factor VIII product (with the exception of short-term use of blood products).\n\nITI substudy:\n\n* PUPs who have developed a confirmed inhibitor to rVIII-SingleChain in the main study.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to rVIII-SingleChain or to any excipients of rVIII-SingleChain or Chinese hamster ovary (CHO) proteins.\n* Currently receiving a therapy not permitted during the study.\n* Serum creatinine \\> 2 x upper limit of normal, alanine aminotransferase or aspartate aminotransferase \\> 5 x upper limit of normal at Screening (if specified)\n* Any first-order family (eg, siblings) history of FVIII inhibitors\n* For PTPs not rolling over directly from a CSL-sponsored clinical study with rVIII-SingleChain: any history of or current FVIII inhibitors","healthyVolunteers":false,"sex":"MALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Inhibitor Formation to FVIII in Previously Treated Patients (PTPs) With 100 Exposure Days (EDs) to CSL627","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Previously Untreated Patients (PUPs) With High-titer Inhibitor Formation to FVIII With at Least 50 EDs to CSL627","description":"High-titer inhibitor is defined as an inhibitor titer of â‰¥ 5 Bethesda units/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent Treatment Success for Major Bleeding Episodes in PUPs","description":"Percentage of major bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of \"excellent\" or \"good\" on the investigator's clinical assessment of hemostatic efficacy 4-point scale \"excellent, good, moderate or poor/no response\". Major bleeding episodes are defined as bleeding episodes for which a subject is required to seek treatment at the hemophilia center or that threatens the subject's life or loss of limb.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Annualized Spontaneous Bleeding Rate in PUPs","description":"The annualized spontaneous bleeding rate for PUPs taking prophylaxis and on-demand treatment regimens.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"2.252"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.04","spread":"6.374"}]}]}]},{"type":"SECONDARY","title":"Percentage of Bleeding Episodes Treated Successfully in PTPs","description":"Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of \"excellent\" or \"good\" on the investigator's clinical assessment of hemostatic efficacy 4-point scale \"excellent, good, moderate or poor/no response\".","paramType":"NUMBER","dispersionType":"99% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Bleeding Rate in PTPs and PUPs","description":"The annualized bleeding rate for PTPs and PUPs taking prophylaxis and on-demand treatment regimens","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.32","spread":"29.014"},{"groupId":"OG001","value":"5.12","spread":"5.331"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"4.981"},{"groupId":"OG001","value":"5.94","spread":"7.705"}]}]}]},{"type":"SECONDARY","title":"Percentage of Bleeding Episodes Requiring 1, 2, 3, or > 3 Injections of CSL627 to Achieve Hemostasis in PTPs and PUPs","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":null},{"groupId":"OG001","value":"77.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of On-demand Infusions of CSL627","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.26","spread":"4.778"},{"groupId":"OG001","value":"1.23","spread":"1.296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.18","spread":"57.335"},{"groupId":"OG001","value":"14.75","spread":"15.547"}]}]}]},{"type":"SECONDARY","title":"Mean On-demand Dose Administered of CSL627","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210.39","spread":"188.106"},{"groupId":"OG001","value":"41.93","spread":"44.643"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2524.69","spread":"2257.278"},{"groupId":"OG001","value":"503.16","spread":"535.712"}]}]}]},{"type":"SECONDARY","title":"Mean Prophylaxis Dose Administered of CSL627","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"380.95","spread":"130.079"},{"groupId":"OG001","value":"389.30","spread":"243.191"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4571.35","spread":"1560.944"},{"groupId":"OG001","value":"4671.54","spread":"2918.288"}]}]}]},{"type":"SECONDARY","title":"Mean Total Amount of CSL627 Administered During Surgery Period in PTPs","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51663.0","spread":"62033.25"}]}]}]},{"type":"SECONDARY","title":"Total Amount of CSL627 Administered During Surgery Period in PUPs","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15693","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5631","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7330","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemostatic Efficacy of rVIII-SingleChain for PTPs and PUPs Who Undergo Surgery","description":"The investigator will rate the efficacy of the rVIII-SingleChain treatment during surgery based on a hemostatic efficacy four point rating scale of \"excellent, good, moderate or poor/no response\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Inhibitor Formation to FVIII in PTPs After 10 EDs and After 50 EDs","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of PTPs and PUPs Developing Antibodies Against CSL627","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of PTPs and PUPs Developing Antibodies to Chinese Hamster Ovary (CHO) Proteins","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of PUPs With High-titer Inhibitor Formation to FVIII After 10 EDs With CSL627","description":"High-titer inhibitor is defined as an inhibitor titer of â‰¥ 5 Bethesda units/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of PUPs With Low-titer Inhibitor Formation to FVIII After 10 EDs and After 50 EDs With CSL627","description":"Low-titer inhibitor is defined as an inhibitor titer of less than 5 Bethesda units/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Total Inhibitor Formation to FVIII in PUPs","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Treatment Success for Non-major Bleeding Episodes in PUPs","description":"Percentage of bleeding episodes treated successfully where treatment success for a bleeding episode is defined as a rating of \"excellent\" or \"good\" on the investigator's clinical assessment of hemostatic efficacy 4-point scale \"excellent, good, moderate or poor/no response\". Non-major bleeding episodes are those not requiring treatment at the hemophilia center or not threatening subject's life or loss of limb.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of PUPs With Clinically Significant Abnormal Vital Signs Values After First Infusion of CSL627","description":"Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of PUPs With Treatment-emergent Clinically Significant Abnormal Vital Signs Values","description":"Vital signs assessments include heart rate, blood pressure, and body temperature. Clinical significance of an abnormality will be assessed by the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":222},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pyrexia","Arthralgia","Headache"]}}}